Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 7

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

Authors Bhutani D, Zonder JA

Received 8 August 2016

Accepted for publication 1 February 2017

Published 19 July 2017 Volume 2017:7 Pages 53—60

DOI https://doi.org/10.2147/BLCTT.S82444

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Professor David Dingli


Divaya Bhutani, Jeffrey A Zonder

Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome inhibitor to be approved for the therapy of multiple myeloma. Carfilzomib is a second-generation proteasome inhibitor with irreversible binding to proteasome and less off-target toxicity. The drug has been approved for use in relapsed/refractory multiple myeloma. In this article, we review the use of carfilzomib as second-line therapy in multiple myeloma. We also review the current standards of care for relapsed/refractory multiple myeloma, with particular focus on the use of carfilzomib in advanced disease.

Keywords: multiple myeloma, carfilzomib, relapsed/refractory
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]